Brief: Hillstream Biopharma Announces Pharmacokinetic Data Of Hsb-1216 Supportive Of Development Strategy And Pre-Clinical Data
10/04/2023 14:36
April 10 (Reuters) - Hillstream BioPharma Inc HILS.O :
* HILLSTREAM BIOPHARMA ANNOUNCES PHARMACOKINETIC DATA OF
HSB-1216
SUPPORTIVE OF ITS DEVELOPMENT STRATEGY AND PRE-CLINICAL DATA
Source text for Eikon: ID:nGNXrN81y
Further company coverage: HILS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing